Gain insight into how principal investigator scarcity, frequent protocol amendments, and uneven site performance undermine ...
In today’s ACT Brief, we highlight new insights from TransCelerate on streamlining clinical data to reduce burden, explore ...
Kygevi (doxecitine and doxribtimine) earned FDA approval as the first treatment for thymidine kinase 2 deficiency, supported by data from a Phase II trial and multiple retrospective studies showing ...
In contrast, by utilizing technology-driven tools more effectively, we can drive efficiencies, improve communication, and ...
Jeneen Donadeo, executive director of portfolio management at TransCelerate, and Laura Galuchie, senior director and ...
Takeda has announced the completion of its 7-year, Phase III TIDES clinical trial (NCT02747927) evaluating the dengue vaccine, Qdenga. Along with an exploratory analysis of a booster dose, TIDES data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback